Private equity firm Bain Capital (BCSF) is paying $3.4 billion to buy a 350-year-old Japanese drugs group fighting diabetes ...

The carve-out acquisition will allow Bain to capitalize on the “promising signs for growth” in the Japanese life sciences ...

Hillenbrand Inc. has announced the sale of a 51% stake in its Milacron injection molding and extrusion business to an ...

Bain Capital, an investment firm that has spread its life sciences bets mainly across companies developing ... multi-billion dollar deal that brings a portfolio of products marketed globally ...

On February 5, the company entered into a definitive agreement to sell an ownership stake of approximately 51% in its Milacron injection ...

Japan's Mitsubishi Chemical said on Friday it will sell pharmaceutical unit Tanabe Mitsubishi Pharma to U.S. private equity ...

Hillenbrand Inc. has announced the sale of a 51 percent stake in its Milacron business to Bain Capital, a leading private investment firm. The transaction, valued at $287 million, is expected to close ...

Bain Capital Specialty Finance , Inc. (NYSE:BCSF), a specialty finance company with a market capitalization of $1.17 billion and trading near its 52-week high of $18.35, announced the issuance of $350 ...

“Following an in-depth portfolio review, we determined that Milacron ... potential synergies and cost savings or the failure of Hillenbrand and Bain Capital or any acquired company, or the Proposed ...

Hillenbrand Inc. has announced the sale of a 51 percent stake in its Milacron injection molding and extrusion machinery ...